Literature DB >> 16728545

GH deficiency in patients irradiated for acromegaly: significance of GH stimulatory tests in relation to the 24 h GH secretion.

A A van der Klaauw1, A M Pereira, S W van Thiel, J W A Smit, E P M Corssmit, N R Biermasz, M Frolich, A Iranmanesh, J D Veldhuis, F Roelfsema, J A Romijn.   

Abstract

BACKGROUND: Radiotherapy for pituitary adenomas frequently leads to GH deficiency (GHD). The characteristics of GH secretion in GHD induced by postoperative radiotherapy for acromegaly are not known. HYPOTHESIS: In the long term, stimulated and spontaneous GH release is not different between patients with GHD treated by postoperative radiotherapy for acromegaly or for other pituitary adenomas. DESIGN/
SUBJECTS: We compared the characteristics of basal and stimulated GH secretion in patients with GHD, who had previously received adjunct radiotherapy after surgery for GH-producing adenomas (n=10) vs for other pituitary adenomas (n=10). All patients had a maximal GH concentration by insulin tolerance test (ITT) of 3 microg/l or less, compatible with severe GHD. Mean time after radiation was 17 and 18.7 years, respectively. Stimulated GH release was also evaluated by infusion of growth hormone-releasing hormone (GHRH), GHRH-arginine and arginine, and spontaneous GH by 10 min blood sampling for 24 h. Pulse analyses were performed by Cluster and approximate entropy. OUTCOMES: There were no differences between both patient groups in stimulated GH concentrations in any test. Spontaneous GH secretion was not different between both patient groups, including basal GH release, pulsatility and regularity. Pulsatile secretion was lost in two acromegalic and three non-acromegalic patients. Insulin-like growth factor-I (IGF-I) was below -2 s.d. score in nine patients in each group.
CONCLUSION: Acromegalic patients treated by surgery and postoperative radiotherapy with an impaired response to the ITT do not differ, in the long term, in GH secretory characteristics from patients treated similarly for other pituitary tumors with an impaired response to the ITT. The ITT (or the GHRH-arginine test) is therefore reliable in establishing the diagnosis of GHD in patients treated for acromegaly by surgery and radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728545     DOI: 10.1530/eje.1.02163

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  4 in total

1.  Growth Hormone Dynamics in Healthy Adults Are Related to Age and Sex and Strongly Dependent on Body Mass Index.

Authors:  Ferdinand Roelfsema; Johannes D Veldhuis
Journal:  Neuroendocrinology       Date:  2015-07-28       Impact factor: 4.914

2.  Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.

Authors:  Karen K Miller; Tamara Wexler; Pouneh Fazeli; Lindsay Gunnell; Gwenda J Graham; Catherine Beauregard; Linda Hemphill; Lisa Nachtigall; Jay Loeffler; Brooke Swearingen; Beverly M K Biller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

3.  Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly.

Authors:  Agatha A van der Klaauw; Jeroen J Bax; Ferdinand Roelfsema; Marcel P M Stokkel; Gabe B Bleeker; Nienke R Biermasz; Johannes W A Smit; Johannes A Romijn; Alberto M Pereira
Journal:  Pituitary       Date:  2009-06-12       Impact factor: 4.107

4.  Severe growth hormone deficiency is rare in surgically-cured acromegalics.

Authors:  Shingo Fujio; Hiroshi Tokimura; Hirofumi Hirano; Ryosuke Hanaya; Fumikatsu Kubo; Shunji Yunoue; Manoj Bohara; Yasuyuki Kinoshita; Atsushi Tominaga; Hiroshi Arimura; Kazunori Arita
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.